PsiOxus Therapeutics, an immuno-oncology company in Oxford, England, has appointed Paolo Paoletti to Chairman of its Board to replace Michael Moore. Moore will remain on the Board as Deputy Chairman.
“I am certain that Paoletti’s proven experience in oncology drug development together with his ability to inspire and lead a growing oncology focused business will be invaluable as we move enadenotucirev, our lead oncolytic viral program, into mid-stage clinical studies and as we accelerate our next generation oncology platform and programs towards the clinic,” stated PsiOxus CEO John Beadle.
Paoletti is the CEO of Kesios Therapeutics based at the Imperial College Incubator, London, England. Previously, Paoletti was the President of GlaxoSmithKline (GSK) Oncology, a global role in which he championed the fight against the causes and impacts of cancer. In this role, he was responsible for R&D, commercial strategy, and lifecycle management, and shared the accountability of GSK Oncology’s P&L with its regional commercial leaders. Prior to GSK, Paoletti was Vice President, Clinical Development for Lilly Oncology.
Paoletti is also a current non-executive director for Genmab, FORMA Therapeutics and Nucana Biomed.
PsiOxus Therapeutics is a development stage biotechnology company with a particular focus on immune therapeutics in oncology. The firm has developed a patented platform for tumour-targeted delivery based on its oncolytic vaccine, enadenotucirev. PsiOxus’ investors include Imperial Innovations, Invesco Perpetua, SR One, Mercia Fund Management and Lundbeckfond Ventures.
